Novartis reportedly in talks to buy MorphoSys; Astellas cuts PhII program; Silence’s $120M private placement

Plus, news about Adverum, BridgeBio Pharma, Vaxcyte, Corbus and Immunocore:

Novartis reportedly in deal talks with MorphoSys: The Swiss Big Pharma is in advanced talks to buy the German drugmaker, Reuters reported Monday, citing unnamed sources. The news outlet also reported that Incyte had made an offer. MorphoSys’ market cap is currently about $2.2 billion, and the biotech’s shares $MOR rose about 45% on the news. — Kyle LaHucik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Boehringer allocates €120M to boost production of Jardiance in Greek plant

Boehringer Ingelheim is undergoing a €120 million expansion of its facility in Koropi, Greece, to boost production of its blockbuster drug Jardiance, among other commercial

January 13, 2024

J&J extends ‘Save Legs’ campaign to drive awareness of peripheral artery disease

Johnson & Johnson is expanding its peripheral artery disease (PAD) health equity campaign for 2024 with new geographies and a new focus on Hispanic patients.

January 12, 2024

Study finds specific gut microbiota signature is associated with vulnerability to food addiction

Researchers of a recent study published in Gut explored gut microbial involvement in food addiction-related processes.

July 1, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.